Vaxcyte (NASDAQ:PCVX) (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae. In addition to the pneumococcal program, the company is advancing VAX-A1, a Group A Streptococcus vaccine candidate, and VAX-B4, which targets Group B Streptococcus. These programs are supported by Vaxcyte’s XpressCF+ bioconjugation technology, which uses in vivo bacterial glycoengineering to generate homogeneous conjugate vaccines without the need for separate carrier protein manufacturing steps.
Since its launch in 2018, Vaxcyte has collaborated with academic and industry partners to accelerate its pipeline. The company initiated its initial public offering in August 2020, securing financing to support ongoing clinical trials and technology development. Vaxcyte’s research operations are centered in the San Francisco Bay Area, and the organization is preparing for late-stage clinical studies with the goal of gaining regulatory approvals in the United States and global markets where pneumococcal and streptococcal diseases impose a heavy public health burden.
Vaxcyte is led by a management team with deep expertise in vaccine research, development, and manufacturing. The company continues to expand its scientific capabilities and manufacturing capacity while exploring additional bacterial targets to further extend the benefits of its bioconjugate platform. Through its ongoing clinical programs and platform innovations, Vaxcyte aims to deliver safer, broader-coverage vaccines that address critical gaps in infectious disease prevention.
